AD 8717

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H591055

CAS#: 181821-99-8

Description: AD 8717

Chemical Structure

img
AD 8717
CAS# 181821-99-8
Instruction

Theoretical Analysis

Hodoodo Cat#: H591055
Name: AD 8717
CAS#: 181821-99-8
Chemical Formula: C22H19Cl2N5O
Exact Mass: 449.17
Molecular Weight: 450.410
Elemental Analysis: C, 58.67; H, 6.49; Cl, 15.74; N, 15.55; O, 3.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AD-8717; AD 8717; AD8717

IUPAC/Chemical Name: 3-Pyridinecarboxamide, 2-(((2,4-dimethoxyphenyl)methyl)sulfinyl)-N-(2,6-dimethyl-4-pyridinyl)-

InChi Key: BDHAPQXDDJQQBI-JPKZNVRTSA-N

InChi Code: InChI=1S/C22H27N5O.2ClH/c1-16-6-5-7-17(12-16)13-27-11-10-26(2)14-18(15-27)23-22(28)21-19-8-3-4-9-20(19)24-25-21;;/h3-9,12,18H,10-11,13-15H2,1-2H3,(H,23,28)(H,24,25);2*1H/t18-;;/m1../s1

SMILES Code: O=C(C1=NNC2=C1C=CC=C2)N[C@H]3CN(CC4=CC=CC(C)=C4)CCN(C)C3.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 450.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2017 Feb 14;116(4):464-471. doi: 10.1038/bjc.2016.436. Epub 2017 Jan 12. PubMed PMID: 28081543; PubMed Central PMCID: PMC5318973.

2: Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Nagai Y, Asami C, Kitagawa Y. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016 Nov 22;115(11):1328-1334. doi: 10.1038/bjc.2016.350. Epub 2016 Nov 3. PubMed PMID: 27811857; PubMed Central PMCID: PMC5129815.

3: Hasegawa Y, Iuchi T, Sakaida T, Yokoi S, Kawasaki K. The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. J Clin Neurosci. 2016 Sep;31:67-71. doi: 10.1016/j.jocn.2015.12.033. Epub 2016 Jul 16. PubMed PMID: 27430412.

4: Kopajtich R, Murayama K, Janecke AR, Haack TB, Breuer M, Knisely AS, Harting I, Ohashi T, Okazaki Y, Watanabe D, Tokuzawa Y, Kotzaeridou U, Kölker S, Sauer S, Carl M, Straub S, Entenmann A, Gizewski E, Feichtinger RG, Mayr JA, Lackner K, Strom TM, Meitinger T, Müller T, Ohtake A, Hoffmann GF, Prokisch H, Staufner C. Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy. Am J Hum Genet. 2016 Aug 4;99(2):414-22. doi: 10.1016/j.ajhg.2016.05.027. Epub 2016 Jul 14. PubMed PMID: 27426735; PubMed Central PMCID: PMC4974065.

5: Fukuda M, Takatori A, Nakamura Y, Suganami A, Hoshino T, Tamura Y, Nakagawara A. Effects of novel small compounds targeting TrkB on neuronal cell survival and depression-like behavior. Neurochem Int. 2016 Jul;97:42-8. doi: 10.1016/j.neuint.2016.04.017. Epub 2016 May 7. PubMed PMID: 27166149.

6: Tada Y, Hiroshima K, Shimada H, Morishita N, Shirakawa T, Matsumoto K, Shingyoji M, Sekine I, Tatsumi K, Tagawa M. A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. Springerplus. 2015 Jul 16;4:358. doi: 10.1186/s40064-015-1123-3. eCollection 2015. PubMed PMID: 26191485; PubMed Central PMCID: PMC4503710.

7: Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16. PubMed PMID: 25880011; PubMed Central PMCID: PMC4430714.

8: Zhong B, Ma G, Sato A, Shimozato O, Liu H, Li Q, Shingyoji M, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. Fas ligand DNA enhances a vaccination effect by coadministered DNA encoding a tumor antigen through augmenting production of antibody against the tumor antigen. J Immunol Res. 2015;2015:743828. doi: 10.1155/2015/743828. Epub 2015 Feb 18. PubMed PMID: 25759847; PubMed Central PMCID: PMC4352480.

9: Gouspillou G, Scheede-Bergdahl C, Spendiff S, Vuda M, Meehan B, Mlynarski H, Archer-Lahlou E, Sgarioto N, Purves-Smith FM, Konokhova Y, Rak J, Chevalier S, Taivassalo T, Hepple RT, Jagoe RT. Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle. Sci Rep. 2015 Mar 3;5:8717. doi: 10.1038/srep08717. PubMed PMID: 25732599; PubMed Central PMCID: PMC4346812.

10: Pergialiotis V, Vlachos DG, Rodolakis A, Thomakos N, Christakis D, Vlachos GD. The effect of vaginal lubrication on unsatisfactory results of cervical smears. J Low Genit Tract Dis. 2015 Jan;19(1):55-61. doi: 10.1097/LGT.0000000000000037. Review. PubMed PMID: 24769651.

11: Murugappan S, Patil HP, Kanojia G, ter Veer W, Meijerhof T, Frijlink HW, Huckriede A, Hinrichs WL. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):716-25. doi: 10.1016/j.ejpb.2013.07.018. Epub 2013 Aug 8. PubMed PMID: 23933147.

12: Yamaki T, Suenaga Y, Iuchi T, Alagu J, Takatori A, Itami M, Araki A, Ohira M, Inoue M, Kageyama H, Yokoi S, Saeki N, Nakagawara A. Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma. Sci Rep. 2013;3:1160. doi: 10.1038/srep01160. Epub 2013 Jan 29. PubMed PMID: 23362460; PubMed Central PMCID: PMC3557454.

13: Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M. Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects. Br J Cancer. 2011 Oct 25;105(9):1302-12. doi: 10.1038/bjc.2011.379. Epub 2011 Sep 27. PubMed PMID: 21952623; PubMed Central PMCID: PMC3241552.

14: Seo DW, Saxinger WC, Guedez L, Cantelmo AR, Albini A, Stetler-Stevenson WG. An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. Peptides. 2011 Sep;32(9):1840-8. doi: 10.1016/j.peptides.2011.08.010. Epub 2011 Aug 16. PubMed PMID: 21871510; PubMed Central PMCID: PMC3177407.

15: Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG. U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):591-9. doi: 10.1158/1055-9965.EPI-10-1183. Epub 2011 Jan 25. PubMed PMID: 21266522; PubMed Central PMCID: PMC3070049.

16: Shingyoji M, Ando S, Nishimura H, Nakajima T, Ishikawa A, Itakura M, Iizasa T, Kimura H. VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel. Anticancer Res. 2009 Jul;29(7):2635-9. PubMed PMID: 19596939.

17: Ma G, Kawamura K, Li Q, Suzuki N, Liang M, Namba M, Shimada H, Tagawa M. Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status. Cancer Gene Ther. 2009 Nov;16(11):832-40. doi: 10.1038/cgt.2009.21. Epub 2009 Apr 10. PubMed PMID: 19363469.

18: Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I, Tagawa M. Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res. 2007 Jul-Aug;27(4B):2311-6. PubMed PMID: 17695519.

19: Tagawa M, Kawamura K, Shimozato O, Ma G, Li Q, Suzuki N, Shimada H, Ochiai T. Virology- and immunology-based gene therapy for cancer. Cancer Immunol Immunother. 2006 Nov;55(11):1420-5. Epub 2006 May 12. Review. PubMed PMID: 16691360.

20: Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N, Uzawa K, Tanzawa H, Shimada H, Ochiai T, Tagawa M. Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep. 2005 Oct;14(4):831-5. PubMed PMID: 16142339.